Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Immatics N.V.    IMTX   NL0015285941

IMMATICS N.V.

(IMTX)
  Report
Delayed Quote. Delayed Nasdaq - 01/26 04:00:00 pm
10.87 USD   -2.69%
01/06IMMATICS N : Corporate Presentation, January 2021
PU
2020Immatics Reports Wider Loss, Higher Revenue in Q3
MT
2020PRESS RELEASE : Immatics Announces Third Quarter -4-
DJ
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Immatics N : ACTolog® IMA101 Phase-1-Data at the 35th Annual SITC conference

11/10/2020 | 07:29am EST
Follow us on

Results of the First-in-human Clinical Trial with Personalized Multi-target Adoptive Cell Therapy (ACTolog® IMA101)

Apostolia M. Tsimberidou1, Kerstin Guenther2, Amir Alpert3, Borje Andersson1, Zoe Coughlin3, Stephen Eck3, Jens Fritsche2, Norbert Hilf2, Patrick Hwu1, Mamta Kalra3, Sabrina Kuttruff-Coqui2, Dominik Maurer2, Regina Mendrzyk2, Ali Mohamed3, Becky Norris1,

Abstr. No. 293

Anna Nowak2, Rita Ort1, Carsten Reinhardt2, Fabian Richter2, Arun Satelli3, Oliver Schoor2, Kerry Sieger3, Harpreet Singh2,3, David Vining1, Claudia Wagner2, Toni Weinschenk2, Cassian Yee1, Steffen Walter3

1 The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA 2 Immatics Biotechnologies GmbH, Paul-Ehrlich-Str.15-17, 72076 Tuebingen, Germany 3 Immatics US, Inc. 2201 Holcombe Blvd., Suite 205, Houston, Texas 77030, USA.

BACKGROUND

RESULTS

Table 3. Treatment-Emergent Adverse Events

Figure 3. Characterization of TCRs in ACTolog®

Background

  • Adoptive cell therapy (ACT) in solid tumors is challenging due to lack of targets with high tumor specificity, tumor heterogeneity and tumor escape by loss of single antigen (Ag) expression.
  • ACTolog® (IMA101) is a personalized multi-target adoptive cell therapy (ACT) approach in which autologous T cell products are directed against multiple novel defined peptide-HLA (pHLA) cancer targets identified by the target discovery platform XPRESIDENT®.
  • ACTolog® target warehouse: COL6A3 exon 6, PRAME, MAGEA1, MAGEA4, MAGEA8, CTAG1A/NY- ESO-1, MXRA5, MMP1. Targeting the novel tumor stroma target COL6A3 exon 6 is intended to disrupt the tumor microenvironment.
  • Tumors positive for ≥1 target from the ACTolog® target warehouse (HLA-A*02:01 restricted targets) are identified using the in vitro diagnostic device IMADetectTM (qPCR assay).
  • Up to 4 tumor-specific T cell products are manufactured from leukapheresis product.
  • Clinical proof of concept in melanoma established (Cassian Yee, MD Anderson) with a single-target T cell product demonstrating T cell persistence long-term at levels >1% and objective responses

Chapuis et al, Sci Transl Med (2013) and Chapuis et al, JCO (2016).

Study Objectives

  • Primary: To evaluate the safety and tolerability of ACTolog® alone (Cohort 1) or in combination with atezolizumab (Cohort 2)
  • Secondary: To evaluate in vivo persistence of transferred T cells and tumor response
  • Exploratory: Ex vivo functionality of transferred T cells, T cell infiltration in the tumor, progression- free survival (PFS) and overall survival (OS)

METHODS

Patients

HLA-A*02:01 positive patients with relapsed/refractory solid tumors whose tumor expressed ≥1 cancer target underwent leukapheresis, and endogenous T cells specific for up to 4 targets were primed and expanded in vitro.

Eligibility criteria are listed in www.clinicaltrials.govNCT02876510.

Treatment (Cohort 1)

  • Preconditioning regimen: fludarabine 40 mg/m² and cyclophosphamide 500 mg/m² on days -6 to -3
  • ACTolog® up to 4x1010 total cells (day 0)
  • IL-2(1x106 IU SC BID, 28 doses)

Patients in Cohort 2also received atezolizumab starting on day 21 or later upon hematologic recovery (1200 mg IV every 3 weeks up to 12 months).

Severity of adverse events (AE) was assessed according to CTCAE v5.0 and AE were coded according to MedDRA. Patients are counted only once per adverse event and severity classification.

Response was assessed by RECIST 1.1 and irRECIST. Progression-free-survival (PFS) was measured from date of entry on the treatment part of the study to date of disease progression or treatment discontinuation. Overall survival (OS) was measured from date of entry on the treatment part of the study until date of death or last follow-up.

All data are as of October 6th, 2020 (unclean data).

Figure 1. ACTolog® Treatment Schema

HLA-A*02:01 (+)

Table 1. Patients Screened and Treated

Screening/Treatment Status

No. of Patients (%)

Screened

214 (100)

HLA-A*02:01-positive

99

(46.3)

Screening tumor biopsy

61 (28.5)*

≥1 Target positive

54

(25.2)

Leukapheresis

43

(20.1)

Cohort 1 (intention-to-treat)

4

(1.9)

Cohort 2 (intention-to-treat)

10 (4.7)

Total treated with T cell product

14 (6.5)

* 60/61 tumor biopsies were evaluable for assessment of target expression.

Table 2. Patient Characteristics and Outcomes

Pt

Age/

No. of

Yrs

Targets

Viable/ Specific Cells

Best

PFS

OS

Tumor Diagnosis

prior

from

Infused per Product

Cohort3

Response

ID

Gender

Positive

[mo]

[mo]

Rx1

Dx2

[x1010]

(wk)4

012

56/F

Breast

10

18

COL6A3,

MXRA5: 0.42/ 0.10

1

SD

2.4

28.4

adenocarcinoma

MXRA5

[4]

(PD)

(D)

PRAME,

PRAME: 1.16/ 0.84

COL6A3,

SD

3.3

22.8

028

28/F

Synovial sarcoma

5

10

MXRA5: 1.02/ 0.42

1

MXRA5,

[4]

(PD)

(D)

NY-ESO-1: 1.37/ 0.59

NY-ESO-1

Myxoid

PRAME,

PRAME: 1.16/ 0.76

SD

4.7

21.6

027

36/M

12

7

COL6A3,

COL6A3: 1.16/ 1.09

1

liposarcoma

[12]

(PD)

(D)

NY-ESO-1

NY-ESO-1: 1.16/ 1.07

048

37/M

SCC of

5

13

COL6A3,

COL6A3: 1.69/ 1.47

1

SD

12.9

22.2

nasopharynx

MMP1

[10]5,6

(PD)

(D)

096

58/F

SCC of anus

8

5

PRAME,

PRAME: 0.97/ 0.49

2

SD

3.4

10.6

COL6A3

COL6A3: 0.76/ 0.26

[6]

(PD)

(D)

Infiltrating duct

COL6A3,

COL6A3: 1.61/ 1.27

SD

3.2

7.9

071

31/F

9

4

PRAME,

2

breast cancer

PRAME: 0.33/ 0.03

[6]

(PD)

(D)

MMP1

PRAME,

PRAME: 1.74/ 1.58

SD

5.8

8.6

095

49/F

Synovial sarcoma

5

4

COL6A3,

COL6A3: 0.91/ 0.63

2

[17]

(PD)

(D)

MXRA5

MXRA5: 1.32/ 0.82

COL6A3,

COL6A3: 1.16/ 0.97

SD

7.3

18.6

139

24/F

Ovarian cancer

4

2

MMP1,

MMP1: 1.41/ 0.85

2

[24]5

(PD)

(A)

MXRA5

MXRA5: 1.16/ 1.00

145

56/F

Invasive duct

3

4

COL6A3,

COL6A3: 1.04/ 0.89

2

PD

1.8

6.7

breast cancer

NY-ESO-1

NY-ESO-1: 1.74/ 1.61

[6]

(PD)

(D)

163

63/F

Mesothelioma of

8

6

PRAME

PRAME: 0.68/ 0.55

2

SD

13.7

13.9

the peritoneum

[52]

(PD)

(A)

173

32/F

Infiltrating duct

8

4

COL6A3

COL6A3: 1.39/ 1.09

2

SD

3.4

4.7

breast cancer

[6]

(PD)

(D)

164

57/F

Colon

5

2

COL6A3

COL6A3: 0.72/ 0.40

2

PD

2.0

4.0

adenocarcinoma

[6]

(PD)

(D)

172

44/F

SCC of anus

3

4

COL6A3

NA7

NA

NA

NA

NA

199

20/F

Small cell sarcoma

7

6

COL6A3

COL6A3: 0.58/ 0.44

2

SD

3.7

3.7

of mandible

[11]5

(SD)

(A)

205

56/F

Colon

4

3

COL6A3,

COL6A3: 0.77/ 0.46

2

PD

1.8

2.9

adenocarcinoma

MMP1

[6]

(PD)

(D)

1 prior systemic treatments. 2 years from diagnosis. 3 intention-to-treat.4 weeks from T cell infusion. 5 Patients did not progress per RECIST1.1 while on study. 6 Left study with SD (RECIST1.1) at week 10 and remained SD for 12.9 months during follow-up without further treatment. 7 The patient received lymphodepletion, but was not infused with T cell product. (D) Deceased; (A) Alive

Feasibility (Table 1, 2)

  • 54 of 60 (90%) evaluable patients who underwent a tumor biopsy were positive for ≥1 target from the ACTolog® target warehouse.
  • Very high ACTolog® cell doses (mostly >1010) were administered.
  • 50% of patients received multi-target ACTolog® products (up to 3).

Clinical Outcome (Table 2)

  • The median PFS was 3.4 months (95% CI, 2.0-7.4 months).
  • The median OS was 10.6 months (95% CI, 4.7-22.8 months).
  • Six (42.9%) of 14 evaluable patients had disease stabilization at 12 weeks. Prolonged disease stabilization was noted in three patients for 12.9 months, 7.3 months, and 13.7 months.

All Grades

≥Grade 3

Adverse event [by MedDRA term]

No.

%

No.

%

Anemia

14

93.3

12

80.0

Neutrophil count decreased

14

93.3

14

93.3

Platelet count decreased

12

80.0

7

46.7

White blood cell count decreased

12

80.0

10

66.7

Nausea

11

73.3

0

Cytokine release syndrome

10

66.7

0

Vomiting

9

60.0

0

Lymphocyte count decreased

8

53.3

8

53.3

Constipation

7

46.7

0

Hyponatremia

6

40.0

0

Fatigue

6

40.0

0

Hypokalemia

5

33.3

1

6.7

Febrile neutropenia

5

33.3

1

6.7

Hypotension

4

26.7

1

6.7

Abdominal pain

3

20.0

1

6.7

Device related infection

2

13.3

2

13.3

Electrocardiogram QT prolonged

1

6.7

1

6.7

Cellulitis

1

6.7

1

6.7

Dysphagia

1

6.7

1

6.7

Mucosal inflammation

1

6.7

1

6.7

Sinus bradycardia

1

6.7

1

6.7

Bacteremia

1

6.7

1

6.7

Staphylococcal bacteremia

1

6.7

1

6.7

Orthostatic hypotension

1

6.7

1

6.7

N=15. All treatment-emergent adverse events (TEAE) with grade 1-2 occurring in ≥6/15 patients and all events with ≥Grade 3 regardless of relatedness to study treatment and irrespectively of severity are presented.

Safety profile (Table 3)

  • The most common TEAEs were expected cytopenias, mostly associated with the lymphodepleting regimen.
  • Grade 1-2 cytokine release syndrome was noted in 10 (71.4%) of 14 treated patients.

Figure 2. T cell Persistence and Tumor Infiltration

a)

T cell Persistence in Blood

b)

T cell Infiltration in Tumor

5

Cells

Pre-Infusion

3.9

4.2

4

Post-Infustion

ofTotal

3

2

1.3

1.8

1.6

%

1

004-4.9e

003-2.9e

002-2.4e

0.2

0.1

002-1.8e

N/A

003-8.4e

0.9

0.6

0

12

28

27

8

96

71

95

39

45

63

73

164

4

0

0

0

0

0

0

0

1

1

1

1

Infused T cells were tracked in patients' blood via flow-cytometry-based immunomonitoring (a) and in tumor biopsy via TCRβ sequencing (b). Target-specific T cells were in most cases not detectable in pre-infusion biopsies.

a)

T cell clone composition

b)

Tracking of T cell clones

c)

TCR functional avidity

of T cell products

4

in the blood

rearrangments)

3

100

2

*

(productive

1

cellsT rearrangments)

PRAME

cellsTof%

50

15

0

% of (productive

cellsTof% rearrangments)(productive

COL6A3

10

*

0

5

*

PRAME Sorted COL6A3 Sorted

0

1

ek

e

ek

ne

e

ek

k

e

k

e

Baseli

ay

ee

W

2

e

W

W

12

W

D

1

W

3

7

Patient #096 entered the study with PD and received two polyclonal T cell products (COL6A3, PRAME). TCRs were identified from the T cell products and functional avidity was determined after TCR re- expression in Jurkat cells. Both products contained clones with high functional avidity (c). The clone with highest avidity gained dominance in the blood post-infusion (*) (a, b). Patient showed 26% tumor shrinkage at 6 weeks, associated with high T cell frequencies at 2 weeks (b). T cell frequencies dropped at 8 weeks (b) and phenotype shifted towards terminal differentiation (data not shown) associated with progression of the patient at 12 weeks.

CONCLUSIONS

  • ACTolog® demonstrates feasibility of a multi-targetmulti-T cell product approach
    • To our knowledge, this is the first demonstration of feasibility of "actively personalized" (Britten et al., Nat Biotech, 2013) ACT directed to multiple defined pHLA targets, where each product combination is guided by confirmed target expression in patient-derived biopsies.
    • The target positivity rate of 90% demonstrated that such a warehouse approach leads to minimal patient attrition due to lack of target expression which is common in other ACT trials.
  • ACTolog® was generally well-tolerated in heavily pretreated patients
  • ACTolog® shows remarkable T cell persistence and tumor infiltration
    • ACTolog® treatment resulted in high target-specific T cell levels and persistence with total frequencies up to ~80% of all peripheral CD8+ T cells in the blood (Figure 2a).
    • Target-specificT cells were detectable in post-treatment tumor biopsies (Figure 2b).
    • Individual TCRs in the endogenous T cell products showed a broad range of avidities, however the majority being of low avidity (EC50>10-8 M, data not shown), reflecting the range to be expected in the natural immune repertoire.
  • ACTolog® revealed long-term disease stabilization in some patients
    • All three patients with prolonged disease stabilization showed high frequency of target- specific T cells (>40% of CD8+ T cells) in the blood post-infusion.
    • Two of these three patients received a COL6A3 exon 6-specific T cell product suggesting that targeting the tumor stroma may be a promising approach.
  • ACTolog® results warrant further evaluation of a multi-target ACT approach using potent high- avidity TCRs (i.e. autologous TCR-engineered T cells)

This work was supported by a Product Development Research Grant from CPRIT (DP150029) Corresponding author: atsimber@mdanderson.org;

Sponsor contact: Steffen.Walter@immatics.com Immatics Biotechnologies GmbH, Immatics US, Inc. www.Immatics.com, info@immatics.com

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Immatics NV published this content on 10 November 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 November 2020 12:28:02 UTC


© Publicnow 2020
All news about IMMATICS N.V.
01/06IMMATICS N : Corporate Presentation, January 2021
PU
2020Immatics Reports Wider Loss, Higher Revenue in Q3
MT
2020PRESS RELEASE : Immatics Announces Third Quarter -4-
DJ
2020PRESS RELEASE : Immatics Announces Third Quarter -3-
DJ
2020PRESS RELEASE : Immatics Announces Third Quarter -2-
DJ
2020PRESS RELEASE : Immatics Announces Third Quarter 2020 Financial Results and Busi..
DJ
2020BofA Securities Starts Immatics at Buy With $13 Price Target
MT
2020IMMATICS N : Factsheet English
PU
2020IMMATICS N : ACTolog® IMA101 Phase-1-Data at the 35th Annual SITC conference
PU
2020Immatics Presents Phase I Data from ACTolog® Multi-Target Pilot Study IMA101 ..
GL
More news
Financials (USD)
Sales 2020 35,6 M - -
Net income 2020 -275 M - -
Net cash 2020 278 M - -
P/E ratio 2020 -1,73x
Yield 2020 -
Capitalization 684 M 684 M -
EV / Sales 2020 11,4x
EV / Sales 2021 13,5x
Nbr of Employees 230
Free-Float 54,7%
Chart IMMATICS N.V.
Duration : Period :
Immatics N.V. Technical Analysis Chart | IMTX | NL0015285941 | MarketScreener
Technical analysis trends IMMATICS N.V.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 17,40 $
Last Close Price 10,87 $
Spread / Highest target 158%
Spread / Average Target 60,1%
Spread / Lowest Target 19,6%
EPS Revisions
Managers and Directors
NameTitle
Harpreet Singh-Jasuja Chief Executive Officer & Managing Director
Peter Alan Chambré Chairman-Supervisory Board
Arnd Christ Chief Financial Officer
Cedrik M. Britten Chief Medical Officer
Steffen Walter Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
IMMATICS N.V.0.74%684
MODERNA, INC.45.35%58 169
LONZA GROUP AG6.79%50 766
CELLTRION, INC.-10.58%39 697
IQVIA HOLDINGS INC.0.65%35 090
SEAGEN INC.-1.43%32 583